Skip to content
drillr.ai

AQST

Aquestive Therapeutics, Inc.

NASDAQ · USHealthcareDrug Manufacturers - Specialty & Generic
$3.94-4.25%

Price as of Jul 20, 2026

AQST news

Aquestive Therapeutics, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Shareholders to Inquire about Securities Investigation

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / June 21, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aquestive Therapeutics, Inc. ("Aquestive" or "the Company") (NASDAQ:AQST). Investors who purchased Aquestive securities prior to June 16, 2025, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AQST. (https://bga

    ACCESSWIRE ·

  2. Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Connect

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / June 18, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aquestive Therapeutics, Inc. ("Aquestive" or "the Company") (NASDAQ:AQST). Investors who purchased Aquestive securities prior to June 16, 2025, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AQST. (https://bga

    ACCESSWIRE ·

  3. Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 28, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aquestive Therapeutics, Inc. ("Aquestive" or "the Company") (NASDAQ:AQST). Investors who purchased Aquestive securities prior to June 16, 2025, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AQST. (https://bgan

    ACCESSWIRE ·

  4. Lifshitz Law PLLC Announces Investigations of Apollo Global Management, Inc. (NYSE:APO), Aquestive Therapeutics, Inc. (NASDAQ:AQST), Boston Scientific (NYSE:BSX), and Eos Energy Enterprises, Inc. (NASDAQ:EOSE)

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 27, 2026 / Lifshitz Law Firm Apollo Global Management, Inc. (NYSE:APO) Lifshitz Law PLLC (https://pr.report/kQ3belhL) announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's leadership figures, including Marc Rowan and Leon Blac

    ACCESSWIRE ·

  5. Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 26, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aquestive Therapeutics, Inc. ("Aquestive" or "the Company") (NASDAQ:AQST). Investors who purchased Aquestive securities prior to June 16, 2025, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AQST. (https://bgan

    ACCESSWIRE ·

  6. Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

    * Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026 * Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union, and the United Kingdom * Completed AQST-108 phase 1 study in subjects with androgenic alopecia with no safety issues observed * Entered into a $150 million debt facility with Oaktree Capital Management, L.P. * Company to host investor call on May 14, 2026, at 8:00am ET WARREN, N.J., May 13, 20

    Globe Newswire ·

  7. Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

    WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the refinancing of its existing debt facility with a new $150 million debt facility with funds managed by Oaktree Capital Management, L.P. (“Oaktree”). This transaction provides additional flexibility to fund t

    Globe Newswire ·

  8. AQST FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026

    AQST FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.faruqilaw.com%2Fattorney%2F22%2Fjames-m-wilson-jr&esheet=54528251&newsitemid=20260504317659&lan=en-US&anchor=James+%28Josh%29+Wilson&index=1&md5=1e5d2d4bce20e8ccef996e6dc5d5b6cc) Encourages Investors Who Suffer

    Business Wire ·

  9. AQST DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - AQST

    New York, New York--(Newsfile Corp. - May 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline. SO WHAT: If you purchased Aquestive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a co

    Newsfile Corp ·

  10. AQST EQUITY ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026

    Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson (https://api.newsfilecorp.com/redirect/PqN0btgaab) Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Aquestive (https://api.newsfilecorp.com/redirect/wE0QpHBEEV) between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (

    Newsfile Corp ·

  11. AQST Deadline: AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit

    AQST Deadline: AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire NEW YORK, May 3, 2026 NEW YORK, May 3, 2026 /PRNewswire/ -- (https://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.html) Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important

    PR Newswire ·

  12. AQST DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - AQST

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 3, 2026 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ:AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline. SO WHAT: If you purchased Aquestive securities during the Class Period you may be entitled to compensation without payment of any out of p

    ACCESSWIRE ·

  13. Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

    New York, New York--(Newsfile Corp. - May 3, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. (NASDAQ: AQST) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Aquestive Therapeutics securities betwee

    Newsfile Corp ·

  14. Pomerantz LLP Notifies Shareholders of Class Action Filing Against Aquestive Therapeutics, Inc. – AQST

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 3, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ:AQST).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purcha

    ACCESSWIRE ·

  15. AQST DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds Aquestive Therapeutics, Inc. Investors to Join the Class Action Lawsuit Today

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 3, 2026 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. (NASDAQ:AQST) and certain of its officers. (https://app.accessnewswire.com/imagelibrary/94aacdad-2f4b-434d-a5ac-de8f3ffd9ff6/image.png) This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securit

    ACCESSWIRE ·

  16. AQST DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action – AQST

    NEW YORK, May 02, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the “Class Period”), of the important May 4, 2026 lead plaintiff deadline. SO WHAT: If you purchased Aquestive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency

    Globe Newswire ·

  17. AQST DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - AQST

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 2, 2026 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ:AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline. SO WHAT: If you purchased Aquestive securities during the Class Period you may be entitled to compensation without payment of any out of p

    ACCESSWIRE ·

  18. Pomerantz LLP Notifies Shareholders of Class Action Against Aquestive Therapeutics, Inc. – AQST

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 2, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ:AQST).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purcha

    ACCESSWIRE ·

  19. AQST 72 HOUR DEADLINE REMINDER: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026

    Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson (https://api.newsfilecorp.com/redirect/gJRgyF5Z1p) Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Aquestive (https://api.newsfilecorp.com/redirect/ppgVaH5xBy) between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (

    Newsfile Corp ·

  20. AQST Deadline: ROSEN, Top Ranked Investor Counsel, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - AQST

    New York, New York--(Newsfile Corp. - May 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline. SO WHAT: If you purchased Aquestive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a co

    Newsfile Corp ·